Skip to main content

Table 1 Patient eligibility criteria

From: Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME): study protocol for a randomised controlled trial

Inclusion criteria
• Ability to provide written informed consent
• Diagnosis with an asymptomatic AAA which is infrarenal in location and measures ≥50 mm on CTA
• Scheduled for an elective open repair of an AAA
• High likelihood of medication compliance within the 2-week period prior to surgery
Exclusion criteria
• Currently taking fenofibrate or related fibrates
• Contraindication to fenofibrate treatment:
o Liver impairment as demonstrated by abnormal AST or ALT tests (>1.5 × ULN)
o Renal impairment as demonstrated by an elevated serum creatinine level (>150 μM)
o Symptomatic gallbladder disease
o Previous reaction to any lipid-modifying medication
• Previous infrarenal abdominal aortic surgery
• Mycotic AAA
• Requirement for emergency or urgent open AAA repair
• Current participation in another drug trial
  1. CTA computed tomographic angiography, AAA abdominal aortic aneurysm, AST aspartate aminotransferase, ALT alanine transaminase, ULN upper limit of normal